- Tempus AI (NASDAQ: TEM) has launched an Advisory Board featuring 13 renowned physicians to enhance precision medicine.
- The Advisory Board will provide strategic guidance on the company's AI-enabled platform's research, product development, and clinical applications.
- The initiative is led by Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus.
Tempus AI, Inc. (TEM, Financial), a leader in AI-driven precision medicine, has announced the formation of its Advisory Board, composed of distinguished medical professionals from prominent institutions across the United States. This board will focus on maintaining high standards and grounding the company's strategy in expert medical knowledge, supporting Tempus's mission to advance precision medicine through artificial intelligence.
The advisory board, led by Dr. Ezra Cohen, comprises 13 notable physicians specializing in various oncology fields. These include directors and professors from prominent institutions like Ohio State University Medical Center, UCLA, MD Anderson Cancer Center, Mayo Clinic, and Vanderbilt-Ingram Cancer Center. The board will play a crucial role in providing strategic guidance on research, product development, and the clinical utility of Tempus's AI-enabled platform.
"Since the beginning, our belief has been that clinical need and strong science must drive our work," stated Dr. Cohen. "Forming the Tempus Advisory Board solidifies this intent, gathering internationally renowned, experienced, and passionate physician leaders to support and guide our scientific and medical direction as we continue to grow and evolve."
The creation of this advisory board marks a significant step for Tempus AI (TEM, Financial) as it seeks to enhance its position in the healthcare technology sector, leveraging the board's collective expertise to drive innovation and improve patient care.
